3-Me-PCP: Chemical Profile, Properties, Research Information and Safety

3-Me-PCP is a synthetic chemical compound that belongs to the arylcyclohexylamine family. Researchers and chemical databases also identify it as 3-Methyl-PCP or meta-methyl-PCP. The compound has attracted attention because of its structural relationship to phencyclidine (PCP) and other arylcyclohexylamine compounds. However, research on 3-Me-PCP remains limited, so its effects and long-term safety profile require careful consideration.

What Is 3-Me-PCP?

3-Me-PCP is the short name for 3-Methyl-PCP. Its systematic chemical name is 1-[1-(3-methylphenyl)cyclohexyl]piperidine. PubChem lists the compound under CID 611899 and records the CAS number 2201-30-1.

Furthermore, 3-Me-PCP has the molecular formula C18H27N and a reported molecular weight of approximately 257.4 g/mol. These identifiers help researchers distinguish this compound from chemically related substances.

Chemical Classification

3-Me-PCP belongs to the arylcyclohexylamine chemical class. Structurally, it contains a cyclohexane ring connected to a piperidine group and a methyl-substituted phenyl group. This structure places it within a broader group of compounds that includes several PCP-related analogues.

Because structurally similar compounds can behave very differently, researchers should not assume that information about another PCP analogue automatically applies to 3-Me.

How Does 3-Me-PCP Relate to PCP?

3-Me is structurally related to phencyclidine. The European Union Early Warning System describes it as the 3-methyl derivative of PCP and notes its structural relationship to other compounds such as 3-MeO and 3-HO-PCP.

However, structural similarity does not mean identical pharmacological activity or safety. Therefore, researchers should evaluate each compound independently rather than transferring conclusions from another substance.

Research and Pharmacology

Available sources describe 3-Me as a dissociative-type compound. Its pharmacological profile has been associated with interaction with the NMDA receptor, although publicly available research remains limited compared with better-studied compounds.

Consequently, there is still uncertainty around its complete pharmacology, toxicity, metabolism, and possible long-term effects. This lack of comprehensive evidence makes responsible scientific interpretation especially important.

3-Me-PCP Chemical Details

The main chemical identifiers are:

• Common name: 3-Me/ 3-Methyl
• Systematic name: 1-[1-(3-methylphenyl)cyclohexyl]piperidine
• CAS number: 2201-30-1
• Molecular formula: C18H27N
• Molecular weight: approximately 257.4 g/mol
• PubChem CID: 611899
• Chemical class: Arylcyclohexylamine

These identifiers are useful when reviewing scientific literature, chemical databases, analytical records, or laboratory documentation.

Safety and Research Considerations

Researchers should treat 3-Me-PCP as a compound requiring appropriate laboratory controls. Its pharmacological effects, toxicity, interactions, and long-term risks are not sufficiently characterized to establish it as a safe substance for human use.

Moreover, psychoactive compounds can produce unpredictable effects, particularly when their purity, concentration, or composition is uncertain. Therefore, unverified material should not be assumed to contain only the stated compound.

Legal controls can also differ between countries and may change over time. Anyone working with 3-Me should therefore check the applicable regulations and institutional requirements before conducting research.

Final Thoughts on 3-Me

3-Me-PCP is a chemically defined arylcyclohexylamine related to, with the molecular formula C18H27N and CAS number 2201-30-1. Current databases provide useful information about its chemical identity, while available reports provide some insight into its classification and research history.

Nevertheless, important questions remain regarding its complete pharmacology, toxicity, metabolism, and long-term effects. For that reason, 3-MeS is best discussed through an evidence-based research perspective rather than as a routine medicine or approved therapeutic product.